J&J jumps on the MFN pricing train
Johnson & Johnson is the latest pharma group to agree a Most-Favoured Nation (MFN) drug pricing deal with the Trump administration to avert tariffs.
FDA turns down Hetlioz for jet lag once again
Vanda will continue to push for approval of Hetlioz for jet lag, despite the FDA saying its trial designs were not satisfactory.
Now Iktos teams up with Pierre Fabre in oncology
As Servier announces its partnership with Paris, France-based Iktos, now Pierre Fabre Laboratories has revealed an integrated collaboration with Iktos
Parabilis scores $305m in bumper biofinancing week
Money has flooded into biotechs this week, with Parabilis raising $305m and five other start-ups closing nine-figure private rounds.
Report says MSD is in talks to buy Revolution Meds
MSD is rumoured to be in talks to buy Revolution Medicines and its KRAS inhibitor pipeline in a deal that could be worth up to $32 billion.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
5th mRNA-Based Therapeutics Summit Europe
The Summit is the leading European industry-focused forum dedicated to accelerating the development of messenger RNA (mRNA) medicines
VuuAI and Amiculum partner to transform content engagement i...
Amiculum, a global health communications agency, has entered into an exciting strategic collaboration with VuuAI, a GenAI-driven content production automation plat
10th Tumor Models Summit San Francisco
Join the West Coast's premier pharma and biotech gathering, the 10th Tumor Models Summit San Francisco, where innovation meets opportunity
The PM Society Careers Event – 18th February 2026
Join us for our popular event to see how your skills and interests could add value to this vital and constantly evolving industry.
Frontiers Health Turns 10
Celebrating a Decade of Innovation and Collaboration in Berlin, November 11–12, 2025 Berlin / November 7th, 2025 | Marking its 10th anniversary,